Yuxuan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuxuan Wu has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Qiudao Wang
School of Life Sciences, East China Normal University, Shanghai, 200241, China
9 shared publicationsYanhong Jiang
Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 shared publicationsYang Yang
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
8 shared publicationsYongrong Lai
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
8 shared publications- Jiaoyang Liao
Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
7 shared publications - Yuming Lu
School of Agriculture and Biology Shanghai Jiao Tong University Shanghai China
7 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Springer Nature in Research Square
Lipid nanoparticle-mediated CDC7 base editing enables synthetic lethal therapy in TP53-mutant liver cancer
TP53-mutant hepatocellular carcinoma (HCC) represents an aggressive molecular subtype with limited therapeutic options and poor responsiveness to current systemic treatments. Synthetic lethal targeting offers a strategy to exploit this otherwise undruggable genetic context, but the clinical translation of many synthetic lethal dependencies remains constrained by the lack of selective and durable therapeutic approaches. Here, we develop a lipid nanoparticle (LNP)-mediated adenine base-editing strategy to therapeutically disrupt CDC7, a synthetic lethal vulnerability in TP53-mutant HCC. LNP-ABE8e-CDC7sg3 efficiently edits the CDC7 splice-donor site, leading to precise loss of CDC7 expression without inducing DNA double-strand breaks. In TP53-mutant HCC cells, CDC7 base editing suppresses MCM2 phosphorylation, inhibits tumor cell proliferation and induces a senescence-associated program. Notably, this senescence response remodels the tumor secretory phenotype, enhances chemokine expression and promotes natural killer (NK) cell immune surveillance. In orthotopic HCC models, a single intravenous administration of LNP-ABE8e-CDC7sg3 achieves efficient in vivo CDC7 editing, significantly suppresses tumor growth and prolongs overall survival. Together, our findings identify CDC7 base editing as a therapeutic strategy for exploiting TP53-associated synthetic lethality in liver cancer and reveal a mechanism linking genome editing-induced senescence to NK-cell-mediated antitumor immunity.
- 20 September 2026
- Published by Springer Nature in Research Square
Open AccessLipid nanoparticle-mediated CDC7 base editing enables synthetic lethal therapy in TP53-mutant liver cancer
TP53-mutant hepatocellular carcinoma (HCC) represents an aggressive molecular subtype with limited therapeutic options and poor responsiveness to current systemic treatments. Synthetic lethal targeting offers a strategy to exploit this otherwise undruggable genetic context, but the clinical translation of many synthetic lethal dependencies remains constrained by the lack of selective and durable therapeutic approaches. Here, we develop a lipid nanoparticle (LNP)-mediated adenine base-editing strategy to therapeutically disrupt CDC7, a synthetic lethal vulnerability in TP53-mutant HCC. LNP-ABE8e-CDC7sg3 efficiently edits the CDC7 splice-donor site, leading to precise loss of CDC7 expression without inducing DNA double-strand breaks. In TP53-mutant HCC cells, CDC7 base editing suppresses MCM2 phosphorylation, inhibits tumor cell proliferation and induces a senescence-associated program. Notably, this senescence response remodels the tumor secretory phenotype, enhances chemokine expression and promotes natural killer (NK) cell immune surveillance. In orthotopic HCC models, a single intravenous administration of LNP-ABE8e-CDC7sg3 achieves efficient in vivo CDC7 editing, significantly suppresses tumor growth and prolongs overall survival. Together, our findings identify CDC7 base editing as a therapeutic strategy for exploiting TP53-associated synthetic lethality in liver cancer and reveal a mechanism linking genome editing-induced senescence to NK-cell-mediated antitumor immunity.
- Open Access
- 25 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: ATF7IP/SETDB1-mediated epigenetic programming regulates thymic homing and T lymphopoiesis of hematopoietic progenitors during embryogenesis
- 25 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: ATF7IP/SETDB1-mediated epigenetic programming regulates thymic homing and T lymphopoiesis of hematopoietic progenitors during embryogenesis
- Open Access
- 18 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Deep learning–guided engineering of SpuFz1 and rational miniaturization of ωRNA enables efficient genome editing
Advancing the performance of programmable genome editing nucleases remains a key challenge in expanding their research and therapeutic applications. Here, we introduce a scalable deep learning–guided protein engineering framework for improving nuclease activity without requiring experimental training data. As a demonstration, we apply this strategy to SpuFz1, a compact Fanzor nuclease of eukaryotic origin, identifying and validating beneficial mutations that produces a multi-mutant variant with an 11.6-fold increase in editing efficiency. In parallel, we use comparative sequence analysis to design and experimentally validate a 75-nt ultrashort ωRNA scaffold, reducing guide RNA length by 79% while maintaining activity. Integration of these optimized components yields enFanzor, a compact genome editing system that achieves editing efficiencies up to 81.9% in mammalian cells, with strong editing performance in both human hematopoietic stem and progenitor cells (HSPCs) and mouse embryos. The outperforming variant developed through this strategy also supports robust CBE and ABE activity. Notably, the shortened ωRNA not only improves nuclease editing specificity but also leads to a substantial increase in base editing efficiency. Together, this work demonstrates the power of combining AI-guided protein optimization with rational RNA design, and establishes a generalizable strategy for engineering next-generation genome editing tools.
- 18 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDeep learning–guided engineering of SpuFz1 and rational miniaturization of ωRNA enables efficient genome editing
Advancing the performance of programmable genome editing nucleases remains a key challenge in expanding their research and therapeutic applications. Here, we introduce a scalable deep learning–guided protein engineering framework for improving nuclease activity without requiring experimental training data. As a demonstration, we apply this strategy to SpuFz1, a compact Fanzor nuclease of eukaryotic origin, identifying and validating beneficial mutations that produces a multi-mutant variant with an 11.6-fold increase in editing efficiency. In parallel, we use comparative sequence analysis to design and experimentally validate a 75-nt ultrashort ωRNA scaffold, reducing guide RNA length by 79% while maintaining activity. Integration of these optimized components yields enFanzor, a compact genome editing system that achieves editing efficiencies up to 81.9% in mammalian cells, with strong editing performance in both human hematopoietic stem and progenitor cells (HSPCs) and mouse embryos. The outperforming variant developed through this strategy also supports robust CBE and ABE activity. Notably, the shortened ωRNA not only improves nuclease editing specificity but also leads to a substantial increase in base editing efficiency. Together, this work demonstrates the power of combining AI-guided protein optimization with rational RNA design, and establishes a generalizable strategy for engineering next-generation genome editing tools.
- 11 March 2026
- Published by Wiley in Journal of Integrative Plant Biology
- Vol. 68 (9) , 3208-3219
CasY7: An optimized Cas12i system for enhanced genome editing in monocot crops
The CRISPR–Cas12 family nucleases, particularly the Cas12i subtypes, are considered promising alternatives to Cas9 for genome editing in plants. We previously developed a new Cas12i variant, CasY7, which has been successfully applied in clinical trials; its performance in plants remains to be investigated. Initial testing in stable transgenic maize and rice showed that the codon‐optimized CasY7 (pCasY7e1) achieved average editing efficiencies of 58.7% and 62.3% across five target sites, respectively, outperforming the typical Cpf1 (pCpf1) control that targets the same sites. To further enhance activity, we fused T5 exonuclease to CasY7 (pCasY7e2), which shifted mutation profiles toward larger deletions, and subsequently integrated an MS2 aptamer into the crRNA scaffold (pCasY7e3). The optimized pCasY7e3 system increased editing efficiencies to 87.7% in maize and 82.9% in rice—approximately 2.7‐fold higher than pCpf1. We further demonstrated multiplexed editing in maize, generating biallelic dwarf mutants, and validated functionality in hexaploid wheat with editing efficiencies up to 58.8%. Overall, our comprehensive validation across 942 transgenic plants confirmed robust editing in maize, rice, and wheat, establishing CasY7 as a high‐efficiency addition to the CRISPR toolkit.
- 11 March 2026
- Published by Wiley in Journal of Integrative Plant Biology
- Vol. 68 (9) , 3208-3219
CasY7: An optimized Cas12i system for enhanced genome editing in monocot crops
The CRISPR–Cas12 family nucleases, particularly the Cas12i subtypes, are considered promising alternatives to Cas9 for genome editing in plants. We previously developed a new Cas12i variant, CasY7, which has been successfully applied in clinical trials; its performance in plants remains to be investigated. Initial testing in stable transgenic maize and rice showed that the codon‐optimized CasY7 (pCasY7e1) achieved average editing efficiencies of 58.7% and 62.3% across five target sites, respectively, outperforming the typical Cpf1 (pCpf1) control that targets the same sites. To further enhance activity, we fused T5 exonuclease to CasY7 (pCasY7e2), which shifted mutation profiles toward larger deletions, and subsequently integrated an MS2 aptamer into the crRNA scaffold (pCasY7e3). The optimized pCasY7e3 system increased editing efficiencies to 87.7% in maize and 82.9% in rice—approximately 2.7‐fold higher than pCpf1. We further demonstrated multiplexed editing in maize, generating biallelic dwarf mutants, and validated functionality in hexaploid wheat with editing efficiencies up to 58.8%. Overall, our comprehensive validation across 942 transgenic plants confirmed robust editing in maize, rice, and wheat, establishing CasY7 as a high‐efficiency addition to the CRISPR toolkit.
- Top Cited Papers
- 3 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 1045-1051
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction. Here we report interim results from an ongoing clinical trial evaluating primary (safety and tolerability) and secondary (lowering of PCSK9 and LDL-C levels) outcomes of a single intravenous dose of YOLT-101 in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C. Six participants (three men and three women) received escalating doses of YOLT-101 (0.2, 0.4 or 0.6 mg kg-1). No grade ≥3 adverse events occurred. Transient and self-limited infusion-related reactions and elevations in liver enzymes were the most common adverse events. A single infusion of YOLT-101 induced dose-dependent and durable reductions in circulating PCSK9 and LDL-C, with sustained reductions of 74.4% and 52.3%, respectively, at 24 weeks in the 0.6 mg kg-1 cohort (n = 3), demonstrating promise for future clinical development. ClinicalTrials.gov registration: NCT06458010 .
- 3 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 1045-1051
Top Cited PapersIn vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction. Here we report interim results from an ongoing clinical trial evaluating primary (safety and tolerability) and secondary (lowering of PCSK9 and LDL-C levels) outcomes of a single intravenous dose of YOLT-101 in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C. Six participants (three men and three women) received escalating doses of YOLT-101 (0.2, 0.4 or 0.6 mg kg-1). No grade ≥3 adverse events occurred. Transient and self-limited infusion-related reactions and elevations in liver enzymes were the most common adverse events. A single infusion of YOLT-101 induced dose-dependent and durable reductions in circulating PCSK9 and LDL-C, with sustained reductions of 74.4% and 52.3%, respectively, at 24 weeks in the 0.6 mg kg-1 cohort (n = 3), demonstrating promise for future clinical development. ClinicalTrials.gov registration: NCT06458010 .
- 27 January 2026
- Published by Springer Nature in Science China Life Sciences
CRISPR-Cas9-mediated uATG introduction in the 5′UTR of the Uox gene for hyperuricemia mouse models: implications for gout and metabolic disorders
Sequence-specific gene knockdown technologies are crucial for fundamental research and therapeutic applications. RNA interference and CRISPR interference, while extensively utilized for gene expression manipulation, face limitations due to their ectopic or transient expression. In this study, we developed a generalizable and efficient method to downregulate gene expression in human 293T cells by introducing de novo upstream ATGs (uATGs) of genes using CRISPR-Cas9-mediated genome editing. Through CRISPR library screening, in-depth sequencing, and flow cytometry analysis, we validated that the introduction of uATGs served as an effective method to suppress protein expression. Our findings further revealed that this strategy can be tailored to diminish endogenous gene expression in tumor cells without affecting the mRNA transcription levels. Importantly, by introducing a uATG into the 5', untranslated region (UTR) of the Uox gene, we successfully established a Uox-knockdown (KD) mouse model of hyperuricemia associated with metabolic disorders. This model demonstrated hyperuricemia, with serum uric acid levels that exceeded 400 µmol L-1, along with renal dysfunction, as indicated by elevated serum creatinine and blood urea nitrogen levels. Examination of the kidneys from 8-week-old Uox-KD mice revealed abnormal histopathological characteristics, including partial dilation of Bowman's capsules and renal tubules, focal nephron collapse and necrosis, and lymphocytic infiltration. In addition, the mice exhibited lipid and glucose metabolism disorders, all while maintaining a normal lifespan. This spontaneous hyperuricemia model has potential as a valuable tool for long-term studies on hyperuricemia and gout. Taken together, we present an efficient approach for the constant suppression of specific gene expression in mammalian cells and the development of a Uox-KD mouse model of hyperuricemia via CRISPR-Cas9-mediated uATG introduction. This offers broad implications for fundamental research and therapeutic applications.
- 27 January 2026
- Published by Springer Nature in Science China Life Sciences
CRISPR-Cas9-mediated uATG introduction in the 5′UTR of the Uox gene for hyperuricemia mouse models: implications for gout and metabolic disorders
Sequence-specific gene knockdown technologies are crucial for fundamental research and therapeutic applications. RNA interference and CRISPR interference, while extensively utilized for gene expression manipulation, face limitations due to their ectopic or transient expression. In this study, we developed a generalizable and efficient method to downregulate gene expression in human 293T cells by introducing de novo upstream ATGs (uATGs) of genes using CRISPR-Cas9-mediated genome editing. Through CRISPR library screening, in-depth sequencing, and flow cytometry analysis, we validated that the introduction of uATGs served as an effective method to suppress protein expression. Our findings further revealed that this strategy can be tailored to diminish endogenous gene expression in tumor cells without affecting the mRNA transcription levels. Importantly, by introducing a uATG into the 5', untranslated region (UTR) of the Uox gene, we successfully established a Uox-knockdown (KD) mouse model of hyperuricemia associated with metabolic disorders. This model demonstrated hyperuricemia, with serum uric acid levels that exceeded 400 µmol L-1, along with renal dysfunction, as indicated by elevated serum creatinine and blood urea nitrogen levels. Examination of the kidneys from 8-week-old Uox-KD mice revealed abnormal histopathological characteristics, including partial dilation of Bowman's capsules and renal tubules, focal nephron collapse and necrosis, and lymphocytic infiltration. In addition, the mice exhibited lipid and glucose metabolism disorders, all while maintaining a normal lifespan. This spontaneous hyperuricemia model has potential as a valuable tool for long-term studies on hyperuricemia and gout. Taken together, we present an efficient approach for the constant suppression of specific gene expression in mammalian cells and the development of a Uox-KD mouse model of hyperuricemia via CRISPR-Cas9-mediated uATG introduction. This offers broad implications for fundamental research and therapeutic applications.
- Open Access
- 12 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012160
Genome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity
Background: Adoptive T-cell therapy has emerged as a promising therapeutic strategy for cancer treatment. However, clinical challenges persist, including the limited ability of CD8+T cells to infiltrate solid tumors and efficiently eliminate tumor cells. Given the critical role of epigenetic mechanisms in antitumor immunity, targeting epigenetic regulators represents a critical step toward optimizing adoptive T-cell therapies for solid tumors. Methods: To investigate the role of KMT5A in CD8+T cell function, we employed CRISPR screening to identify KMT5A as a negative regulator. We then genetically deleted KMT5A in human CD8+T cells and systematically evaluated its impact on the antitumor efficacy of chimeric antigen receptor (CAR)-T cells using xenograft models. Furthermore, we used the small-molecule inhibitor UNC0379 to pharmacologically inhibit KMT5A, meticulously assessing the consequent effects on CAR-T cell activation, cytotoxicity, and antitumor activity. Results: We report that lysine methyltransferase KMT5A acts as a negative regulator of CD8+T cell function, identified via CRISPR screening. KMT5A deletion in human CD8+T cells significantly enhances the antitumor efficacy of CAR CD8+T cells in xenograft models. In vitro immunophenotyping reveals that KMT5A deletion improves effector functions, cytokine secretion, and early activation of CD8+T cells. Mechanistically, KMT5A depletion increases the expression and chromatin accessibility of multiple effector-related genes in CD8+T cells. KMT5A-mediated histone H4 modifications and chromatin remodeling suppress CD8+T cell effector functions, partially via inhibition of the transcription factor SP1. Notably, pharmacological inhibition of KMT5A using the small-molecule inhibitor UNC0379 enhanced activation, cytotoxicity, and antitumor activity in human CD8+T cells—a novel finding in this study. Conclusions: Our findings establish KMT5A as an epigenetic regulator that impairs CD8+T cell function. These findings demonstrate that genetic or pharmacological (eg, UNC0379) targeting of KMT5A in CD8+T cells represents a viable therapeutic strategy to augment effector functions and improve adoptive T-cell therapies, particularly CAR-T cells, for solid tumors.
- 12 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012160
Open AccessGenome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity
Background: Adoptive T-cell therapy has emerged as a promising therapeutic strategy for cancer treatment. However, clinical challenges persist, including the limited ability of CD8+T cells to infiltrate solid tumors and efficiently eliminate tumor cells. Given the critical role of epigenetic mechanisms in antitumor immunity, targeting epigenetic regulators represents a critical step toward optimizing adoptive T-cell therapies for solid tumors. Methods: To investigate the role of KMT5A in CD8+T cell function, we employed CRISPR screening to identify KMT5A as a negative regulator. We then genetically deleted KMT5A in human CD8+T cells and systematically evaluated its impact on the antitumor efficacy of chimeric antigen receptor (CAR)-T cells using xenograft models. Furthermore, we used the small-molecule inhibitor UNC0379 to pharmacologically inhibit KMT5A, meticulously assessing the consequent effects on CAR-T cell activation, cytotoxicity, and antitumor activity. Results: We report that lysine methyltransferase KMT5A acts as a negative regulator of CD8+T cell function, identified via CRISPR screening. KMT5A deletion in human CD8+T cells significantly enhances the antitumor efficacy of CAR CD8+T cells in xenograft models. In vitro immunophenotyping reveals that KMT5A deletion improves effector functions, cytokine secretion, and early activation of CD8+T cells. Mechanistically, KMT5A depletion increases the expression and chromatin accessibility of multiple effector-related genes in CD8+T cells. KMT5A-mediated histone H4 modifications and chromatin remodeling suppress CD8+T cell effector functions, partially via inhibition of the transcription factor SP1. Notably, pharmacological inhibition of KMT5A using the small-molecule inhibitor UNC0379 enhanced activation, cytotoxicity, and antitumor activity in human CD8+T cells—a novel finding in this study. Conclusions: Our findings establish KMT5A as an epigenetic regulator that impairs CD8+T cell function. These findings demonstrate that genetic or pharmacological (eg, UNC0379) targeting of KMT5A in CD8+T cells represents a viable therapeutic strategy to augment effector functions and improve adoptive T-cell therapies, particularly CAR-T cells, for solid tumors.
- Open Access
- 2 September 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 602
Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model
Personalized neoantigen peptide vaccines have shown remarkable anti-tumor activity across diverse cancer types. With the rapid advancement of messenger RNA (mRNA) delivery technologies during the coronavirus disease of 2019 (COVID-19) pandemic, mRNA-based cancer vaccines have emerged as a promising therapeutic approach because of their scalable production, safety, and capacity to elicit potent immune responses. However, the predominant distribution of mRNA delivery systems in the liver may lead to hepatic damage and restrict therapeutic accessibility. In this study, we designed a novel ionizable lipid library to shift the delivery to the spleen. By incorporating an additional anionic lipid, we identified an optimized vaccine formulation, which exhibited efficient uptake by dendritic cells (DCs). Notably, this formulation achieved spleen-selective delivery without requiring targeting ligand modifications, thereby minimizing cytotoxicity risks. Furthermore, the spleen-targeted L242-20Lipo nanoparticle was employed to facilitate the efficient delivery of personalized neoantigen mRNA vaccines. Evaluation in a hepatocellular carcinoma (HCC) model demonstrated that the NeoPol-mL242 mRNA vaccine elicited potent anti-tumor immunity while maintaining an excellent safety profile. These results highlight NeoPol-mL242 as a promising candidate for application in cancer immunotherapy.
- 2 September 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 602
Open AccessSpleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model
Personalized neoantigen peptide vaccines have shown remarkable anti-tumor activity across diverse cancer types. With the rapid advancement of messenger RNA (mRNA) delivery technologies during the coronavirus disease of 2019 (COVID-19) pandemic, mRNA-based cancer vaccines have emerged as a promising therapeutic approach because of their scalable production, safety, and capacity to elicit potent immune responses. However, the predominant distribution of mRNA delivery systems in the liver may lead to hepatic damage and restrict therapeutic accessibility. In this study, we designed a novel ionizable lipid library to shift the delivery to the spleen. By incorporating an additional anionic lipid, we identified an optimized vaccine formulation, which exhibited efficient uptake by dendritic cells (DCs). Notably, this formulation achieved spleen-selective delivery without requiring targeting ligand modifications, thereby minimizing cytotoxicity risks. Furthermore, the spleen-targeted L242-20Lipo nanoparticle was employed to facilitate the efficient delivery of personalized neoantigen mRNA vaccines. Evaluation in a hepatocellular carcinoma (HCC) model demonstrated that the NeoPol-mL242 mRNA vaccine elicited potent anti-tumor immunity while maintaining an excellent safety profile. These results highlight NeoPol-mL242 as a promising candidate for application in cancer immunotherapy.
- Open Access
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadx9221
Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity
CD8 + T play essential roles in antitumor immune responses. However, immunotherapy has limited clinical efficacy in many solid tumors. Here, we performed an epigenetic-wide CRISPR-Cas9 screen in CD8 + T cells directly under cancer immunotherapy setting and found that Prdm12 is a transcriptional repressor implicated in nociceptive neuron development but uncharacterized within immunological contexts. Prdm12 deletion markedly enhanced in vivo tumor clearance of mouse CD8 + T cells and promoted activation, effector differentiation marker expression, and cytokine secretion in both murine and human CD8 + T cells in vitro. Mechanistically, Prdm12 deficiency augmented effector transcriptional programs while inhibiting exhaustion of CGRP-RAMP1 neuroimmune axis facilitation. Additionally, Prdm12 ablation remodeled the chromatin accessibility landscape, with H3K9me3 deposition at loci regulating T cell differentiation ( Trib1 and Sgk1 ) and exhaustion ( Rgs1 and Nr4a2 ). These results together reveal a negative regulatory mechanism for CD8 + T cells and advance our understanding of cancer immunotherapy by linking neurobiological signaling to immune regulation.
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadx9221
Open AccessPrdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity
CD8 + T play essential roles in antitumor immune responses. However, immunotherapy has limited clinical efficacy in many solid tumors. Here, we performed an epigenetic-wide CRISPR-Cas9 screen in CD8 + T cells directly under cancer immunotherapy setting and found that Prdm12 is a transcriptional repressor implicated in nociceptive neuron development but uncharacterized within immunological contexts. Prdm12 deletion markedly enhanced in vivo tumor clearance of mouse CD8 + T cells and promoted activation, effector differentiation marker expression, and cytokine secretion in both murine and human CD8 + T cells in vitro. Mechanistically, Prdm12 deficiency augmented effector transcriptional programs while inhibiting exhaustion of CGRP-RAMP1 neuroimmune axis facilitation. Additionally, Prdm12 ablation remodeled the chromatin accessibility landscape, with H3K9me3 deposition at loci regulating T cell differentiation ( Trib1 and Sgk1 ) and exhaustion ( Rgs1 and Nr4a2 ). These results together reveal a negative regulatory mechanism for CD8 + T cells and advance our understanding of cancer immunotherapy by linking neurobiological signaling to immune regulation.